search
Back to results

Optimizing Behavioral Healthcare Delivery Through Technology

Primary Purpose

Mood Disorders, Anxiety Disorders

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cognitive behavioral therapy with AI
Cognitive behavioral therapy
Sponsored by
Eleos Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mood Disorders focused on measuring Mood Disorders, Anxiety Disorders, Evidence-Based Practices, Community-Based Clinics, Artificial Intelligence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Older than 18 years old. Presenting for an outpatient CBT for a depressive or anxiety disorder. Exclusion Criteria: Age <18. individuals who are medically unstable for outpatient treatment. a severe mental health condition that might interfere with treatment compliance (e.g., psychotic depression, psychosis, active substance dependence).

Sites / Locations

  • The Ozark Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

The Eleos Health Platform

Treatment as Usual

Arm Description

Therapists in the AI group will use the HIPAA-compliant, secure, password-protected Eleos Health platform. This AI tool was designed for behavioral health to support clinical decision-making and automation of administrative tasks. The platform captures the therapist and patient's utterances during a treatment session, analyzes the data, and offers feedback on the implementation of EBPs. The platform also incorporates a measurement-based care component, wherein standardized assessment scales completed by clients are immediately summarized and graphed for the therapist, who can use these data to inform therapy and share them with the patient. Insights and key indicators from the session data and MBC are summarized into a progress note draft which the therapist can then submit or edit as needed.

Participants randomized to the control group will receive the routine services provided in the center. Therapists providing TAU will be permitted to use the strategies they deen would be most successful.

Outcomes

Primary Outcome Measures

Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is intended as a tool to assist clinicians with identifying and diagnosing depression.
Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is intended as a tool to assist clinicians with identifying and diagnosing depression.
Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is intended as a tool to assist clinicians with identifying and diagnosing depression.
Generalized Anxiety Disorder-7 (GAD-7)
The GAD-7 is intended as a tool to assist clinicians with identifying and diagnosing anxiety.
Generalized Anxiety Disorder-7 (GAD-7)
The GAD-7 is intended as a tool to assist clinicians with identifying and diagnosing anxiety.
Generalized Anxiety Disorder-7 (GAD-7)
The GAD-7 is intended as a tool to assist clinicians with identifying and diagnosing anxiety.

Secondary Outcome Measures

Full Information

First Posted
February 7, 2023
Last Updated
February 15, 2023
Sponsor
Eleos Health
Collaborators
Missouri Department of Mental Health
search

1. Study Identification

Unique Protocol Identification Number
NCT05745103
Brief Title
Optimizing Behavioral Healthcare Delivery Through Technology
Official Title
Optimizing Behavioral Healthcare Delivery Through Technology
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
April 30, 2023 (Anticipated)
Study Completion Date
April 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eleos Health
Collaborators
Missouri Department of Mental Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this randomized controlled clinical trial is to determine the feasibility, acceptability, and preliminary efficacy of an artificial intelligence platform )שׁ( for behavioral health in facilitating better clinical outcomes for adult patients receiving outpatient therapy. The main question[s] it aims to answer are: whether an AI platform designed for behavioral healthcare would be feasible and acceptable to patients and therapists. whether the depression and anxiety outcomes of adults receiving outpatient cognitive-behavioral therapy (CBT) in a community-based clinic would be superior among patients whose therapists used an AI-based platform to support clinical decision making and administrative tasks compared to patients receiving treatment-as-usual (TAU). Participants will receive CBT for depression or anxiety and complete standardized assessments. Participants will be followed for the first two months of therapy.
Detailed Description
The need for scalable delivery of mental health care services that are efficient and effective is now a major public health priority. Artificial intelligence (AI) tools have the potential to improve behavioral healthcare services by helping clinicians collect objective data on patients' progress, streamline their workflow, and automate administrative tasks. The goal of this study is to determine the feasibility, acceptability, and preliminary efficacy of an AI platform for behavioral health in facilitating better clinical outcomes for patients receiving outpatient therapy. This open randomized clinical trial will compare an AI platform provided by Eleos Health to treatment-as-usual (TAU) during the first 2 months of therapy. The study will be conducted at a community-based clinic in the U.S. Participants will be adults referred for outpatient, individual cognitive behavioral therapy for a main diagnosis of a depressive or anxiety disorder. Patients will be randomized to receive either therapy provided with the support of an AI platform developed by Eleos Health or TAU at the same clinic. Data analysis will be carried out based on intention-to-treat principle. The primary outcomes include the feasibility and acceptability of the AI platform. Secondary outcomes include changes in depression (Patient Health Questionnaire-9) and anxiety (Generalized Anxiety Disorder-7) scores as well as treatment attendance and satisfaction. Findings of this study will inform the optimization of future trials and services offered to individuals seeking mental health support in the U.S.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mood Disorders, Anxiety Disorders
Keywords
Mood Disorders, Anxiety Disorders, Evidence-Based Practices, Community-Based Clinics, Artificial Intelligence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Open Randomized Controlled Trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
The Eleos Health Platform
Arm Type
Experimental
Arm Description
Therapists in the AI group will use the HIPAA-compliant, secure, password-protected Eleos Health platform. This AI tool was designed for behavioral health to support clinical decision-making and automation of administrative tasks. The platform captures the therapist and patient's utterances during a treatment session, analyzes the data, and offers feedback on the implementation of EBPs. The platform also incorporates a measurement-based care component, wherein standardized assessment scales completed by clients are immediately summarized and graphed for the therapist, who can use these data to inform therapy and share them with the patient. Insights and key indicators from the session data and MBC are summarized into a progress note draft which the therapist can then submit or edit as needed.
Arm Title
Treatment as Usual
Arm Type
Active Comparator
Arm Description
Participants randomized to the control group will receive the routine services provided in the center. Therapists providing TAU will be permitted to use the strategies they deen would be most successful.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive behavioral therapy with AI
Intervention Description
Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. The Eleos Health platform provides real-time data that optimizes this therapy and helps the provider tailor the intervention to the specific client.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive behavioral therapy
Intervention Description
Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders.
Primary Outcome Measure Information:
Title
Patient Health Questionnaire-9 (PHQ-9)
Description
The PHQ-9 is intended as a tool to assist clinicians with identifying and diagnosing depression.
Time Frame
Baseline
Title
Patient Health Questionnaire-9 (PHQ-9)
Description
The PHQ-9 is intended as a tool to assist clinicians with identifying and diagnosing depression.
Time Frame
1 month
Title
Patient Health Questionnaire-9 (PHQ-9)
Description
The PHQ-9 is intended as a tool to assist clinicians with identifying and diagnosing depression.
Time Frame
2 months
Title
Generalized Anxiety Disorder-7 (GAD-7)
Description
The GAD-7 is intended as a tool to assist clinicians with identifying and diagnosing anxiety.
Time Frame
Baseline
Title
Generalized Anxiety Disorder-7 (GAD-7)
Description
The GAD-7 is intended as a tool to assist clinicians with identifying and diagnosing anxiety.
Time Frame
1 month
Title
Generalized Anxiety Disorder-7 (GAD-7)
Description
The GAD-7 is intended as a tool to assist clinicians with identifying and diagnosing anxiety.
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Older than 18 years old. Presenting for an outpatient CBT for a depressive or anxiety disorder. Exclusion Criteria: Age <18. individuals who are medically unstable for outpatient treatment. a severe mental health condition that might interfere with treatment compliance (e.g., psychotic depression, psychosis, active substance dependence).
Facility Information:
Facility Name
The Ozark Center
City
Joplin
State/Province
Missouri
ZIP/Postal Code
64804
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Optimizing Behavioral Healthcare Delivery Through Technology

We'll reach out to this number within 24 hrs